This 2018 report from the Institute for Clinical and Economic Review compared the evidence for effectiveness and value of new extended-release medications for opioid use disorder (two buprenorphine injections, one buprenorphine implant, and naltrexone injection). This report also includes a description of the discussion of the report at the New England Comparative Effectiveness Public Advisory Council and the recommendations the council made as to how the evidence review should be reflected in policy.
Funding Source: Laura and John Arnold Foundation, along with additional unspecified government and foundation grants
Extended-Release Opioid Agonists and Antagonist Medications for Addiction Treatment (MAT) in Patients with Opioid Use Disorder: Effectiveness and Value
A comparative effectiveness review of extended release treatments for medication assisted treatment of opioid use disorder